Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Leuprolide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR known ✓ | P30968 | 2/20 | 0.86 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.84 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.80 |
| ▸ | APLNR | P35414 | 4/20 | 0.65 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leuprolide SCHEMBL7751433 | 1.00 | GNRHR (0.86) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Deslorelin SCHEMBL1649660 | 1.00 | GNRHR (0.86) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL10061885 | 1.00 | GNRHR (0.86) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL21540132 | 1.00 | GNRHR (0.86) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL3915060 | 0.99 | GNRHR (0.86) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL6448301 | 0.99 | GNRHR (0.86) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| SCHEMBL21109135 | 0.99 | GNRHR (0.84) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL570851 | 0.99 | ABCC2 (0.87) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL847084 | 0.99 | ABCC2 (0.87) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL3174 | 0.99 | ABCC2 (0.87) | GNRHRABCC2PTGS1APLNRCXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 100849 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746898-A2 | IDENTIFICATION OF SEQUENCE VARIANTS OF THE ERVMER34-1 SEQUENCE FAMILY AND USE IN ANTI-CANCER THERAPIES | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4748859-A2 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | The Regents of the University of California (US) | 2026-05-27 | — | — | EP | claimed |
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| CN-116209439-B | Cereblon protein modulators | Saint Jude Children's Research Hospital Ltd. (US) | 2026-05-26 | — | — | CN | claimed |
| WO-2026106718-A2 | MULTI-DOSE INJECTION PEN FOR LEUPROLIDE | Meitheal Pharmaceuticals Inc. (US) | 2026-05-21 | — | — | WO | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| EP-4745155-A1 | POWDER CONTAINING PARTICLES OF GELATIN DERIVATIVE AND APPLICATION OF SAME IN MEDICAL TREATMENT | National Institute for Materials Science (JP) | 2026-05-20 | — | — | EP | claimed |
| US-12629370-B2 | Treatment of prostate cancer | Sumitomo Pharma Co., Ltd. (JP) | 2026-05-19 | — | — | US | claimed |
| WO-2026102332-A1 | NERVE AND TUMOR HOMING AGENTS AND METHODS OF USE THEREOF | Blaze Bioscience, Inc. (US) | 2026-05-15 | — | — | WO | claimed |
| US-5147296-A | For controlling agent delivery | ALZA CORPORATION (US) | 1992-09-15 | — | — | US | claimed |
| US-5080646-A | MEMBRANE FOR ELECTROTRANSPORT TRANSDERMAL DRUG DELIVERY | ALZA CORPORATION (US) | 1992-01-14 | — | — | US | claimed |
| CN-1055663-A | HETEROVESICULAR LIPOSOMES | RES DEV FOUNDATION (US) | 1991-10-30 | — | — | CN | claimed |
| WO-1991014445-A1 | HETEROVESICULAR LIPOSOMES | RESEARCH DEVELOPMENT FOUNDATION (US) | 1991-10-03 | — | — | WO | claimed |
| WO-1991008795-A2 | IMPROVED IONTOPHORETIC DELIVERY METHOD | ALZA CORPORATION (US) | 1991-06-27 | — | — | WO | claimed |
| WO-1990008537-A1 | PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION | ABBOTT LABORATORIES (US) | 1990-08-09 | — | — | WO | claimed |
| US-4927408-A | For placement on a body surface/delivering agent through | ALZA CORPORATION (US) | 1990-05-22 | — | — | US | claimed |
| US-4878892-A | BATTERY POWERED | DRUG DELIVERY SYSTEMS INC. (US) | 1989-11-07 | — | — | US | claimed |
| EP-0312052-A1 | Intranasal administration of polypeptides in powdered form | SYNTEX (U.S.A.) INC. (US) | 1989-04-19 | — | — | EP | claimed |
| EP-0278474-A1 | Electrolytic transdermal delivery of polypeptides | Drug Delivery Systems Inc. (US) | 1988-08-17 | — | — | EP | claimed |